SG11201804857WA - Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof - Google Patents

Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof

Info

Publication number
SG11201804857WA
SG11201804857WA SG11201804857WA SG11201804857WA SG11201804857WA SG 11201804857W A SG11201804857W A SG 11201804857WA SG 11201804857W A SG11201804857W A SG 11201804857WA SG 11201804857W A SG11201804857W A SG 11201804857WA SG 11201804857W A SG11201804857W A SG 11201804857WA
Authority
SG
Singapore
Prior art keywords
tl1a
california
antigen binding
international
binding proteins
Prior art date
Application number
SG11201804857WA
Inventor
Hailing Hsu
Gunasekaran Kannan
Kenneth W Walker
Michelle Hortter
Edward J Belouski
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/052006 external-priority patent/WO2017049004A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11201804857WA publication Critical patent/SG11201804857WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

v) (v3) 3S5! (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/106383 A4 22 June 2017 (22.06.2017) WIPO I PCT (51) International Patent Classification: C07K 16/24 (2006.01) (21) International Application Number: PCT/US2016/066722 (22) International Filing Date: 14 December 2016 (14.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/268,432 16 December 2015 (16.12.2015) US 62/333,063 6 May 2016 (06.05.2016) US PCT/US2016/052006 15 September 2016 (15.09.2016) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). (72) Inventors: HSU, Hailing; 7264 Littler Court, Moorpark, California 93021 (US). KANNAN, Gunasekaran; 151 Crestview Circle, Daly City, California 94015 (US). WALKER, Kenneth W.; 175 Mesa Avenue, Newbury Park, California 91320 (US). HORTTER, Michelle; 455 Mariposa Drive, Camarillo, California 93012 (US). BE- LOUSKI, Edward J.; 761 Camino Las Conchas, Thou- sand Oaks, California 91360 (US). (74) Agents: GAUL, Timothy J. et al.; Amgen Inc., One Am- gen Center Drive, Thousand Oaks, California 91320-1799 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) [Continued on next page] — (54) Title: ANTI-TL1A/ANTI-TNF-ALPHA BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF 1111111111111101110101011111010111110 010110111111011111111011111111111011111111 (v4) K392D :356K K4090 399K K3700 357K W O 20 17 / 106383 A4 HC1 SISaK HC1 039K & • .6.3K HC1 48K & S .61 . HC1 SifLi HC2 S183E HC2 039E & S183E HC2 G44E & S183E HC2 S183E LC1 S176E LC1 0.38E & S176E LC1 GlOOE & S176E LC1 S176E LC2 S176K LC2 038K & S: 76K LC2 i100K & S .76K LC2 S176k Fig_ 1 (57) : The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding pro- teins (e.g., antibodies) to TL1A and TNF-a. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-a. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-alpha antigen binding proteins, and pharmaceutical formulations thereof. WO 2017/106383 A4 MIDEDIMOMOIDEIRMEMOMM1110110MMOMEION with amended claims (Art. 190)) Date of publication of the amended claims: 8 September 2017 with sequence listing part of description (Rule 5.2(a))
SG11201804857WA 2015-12-16 2016-12-14 Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof SG11201804857WA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562268432P 2015-12-16 2015-12-16
US201662333063P 2016-05-06 2016-05-06
PCT/US2016/052006 WO2017049004A1 (en) 2015-09-15 2016-09-15 Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
PCT/US2016/066722 WO2017106383A1 (en) 2015-12-16 2016-12-14 Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
SG11201804857WA true SG11201804857WA (en) 2018-07-30

Family

ID=59057540

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912002YA SG10201912002YA (en) 2015-12-16 2016-12-14 Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
SG11201804857WA SG11201804857WA (en) 2015-12-16 2016-12-14 Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201912002YA SG10201912002YA (en) 2015-12-16 2016-12-14 Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof

Country Status (24)

Country Link
US (2) US11104745B2 (en)
EP (1) EP3390444A1 (en)
JP (1) JP7263007B2 (en)
KR (1) KR20180099723A (en)
CN (1) CN109311971A (en)
AU (2) AU2016370659B2 (en)
BR (1) BR112018012096A2 (en)
CA (1) CA3008267A1 (en)
CL (3) CL2018001596A1 (en)
CO (1) CO2018007355A2 (en)
CR (1) CR20180365A (en)
EA (1) EA201891322A1 (en)
IL (1) IL259847A (en)
JO (1) JO3816B1 (en)
MA (1) MA44060A (en)
MX (1) MX2018007424A (en)
PH (1) PH12018501284A1 (en)
SG (2) SG10201912002YA (en)
TN (1) TN2019000275A1 (en)
TW (1) TWI799368B (en)
UA (1) UA124305C2 (en)
UY (1) UY37027A (en)
WO (1) WO2017106383A1 (en)
ZA (1) ZA201904491B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
CA2850549C (en) 2011-09-30 2023-03-14 Teva Pharmaceuticals Australia Pty Ltd. Antibodies against tl1a and uses thereof
UY35148A (en) * 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
EP3639841B1 (en) 2013-03-27 2023-09-06 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
TWI703158B (en) 2015-09-18 2020-09-01 美商希佛隆公司 Antibodies that specifically bind to tl1a
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
TW201904588A (en) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 Methods of making and using guidance and navigation control proteins
EP3456738B1 (en) 2017-09-19 2024-07-17 Tillotts Pharma Ag Antibody variants
EP3735270A1 (en) * 2018-01-05 2020-11-11 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
WO2019209995A2 (en) 2018-04-25 2019-10-31 Precision Ibd, Inc. Optimized anti-tl1a antibodies
CN111909268B (en) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 anti-TNF-alpha humanized monoclonal antibody TCX060 with low immunogenicity and low ADCC/CDC function and application thereof
CA3140029A1 (en) * 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices
EP3998286A4 (en) * 2019-07-11 2023-04-26 Wuhan Yzy Biopharma Co., Ltd. Tetravalent symmetric bispecific antibody
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
BR112022007720A2 (en) 2019-10-24 2022-08-23 Prometheus Biosciences Inc HUMANIZED ANTIBODIES TO TNF-LIKE BINDING 1A (TL1A) AND THEIR USES
CN113121696A (en) * 2019-12-31 2021-07-16 周易 Bispecific antibody formed by Fab modification induction and preparation method and application thereof
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
JP2023530046A (en) * 2020-04-02 2023-07-13 ラ ホヤ インスティテュート フォー イムノロジー Methods and combinations for dual targeting of TNF family members
US20230203134A1 (en) * 2020-05-20 2023-06-29 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
AU2021306709A1 (en) 2020-07-06 2023-02-09 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting SARS-CoV-2
MX2023000949A (en) 2020-07-23 2023-02-22 Othair Prothena Ltd Anti-abeta antibodies.
JP2023538897A (en) * 2020-08-20 2023-09-12 アムジエン・インコーポレーテツド Antigen binding proteins with non-canonical disulfides in the Fab region
IL300720A (en) 2020-08-26 2023-04-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting sars-cov-2

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
JP3202999B2 (en) 1991-01-31 2001-08-27 協和醗酵工業株式会社 Hepatic liposome preparation
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
ES2284247T3 (en) 1998-04-03 2007-11-01 University Of Iowa Research Foundation METHODS AND PRODUCTS TO STIMULATE THE IMMUNITY SYSTEM USING OLIGONUCLEOTIDES AND IMMUNOTHERAPEUTIC CYTOQUINS.
KR20130105766A (en) 1999-03-25 2013-09-25 애보트 게엠베하 운트 콤파니 카게 Human antibodies that bind human il-12 and methods for producing
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU783682B2 (en) 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
EP1667730B1 (en) 2003-08-20 2013-06-26 University of Miami Compositions and methods for treating inflammatory lung disease
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US9068003B2 (en) 2007-01-10 2015-06-30 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
UA104132C2 (en) 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
JP5522405B2 (en) 2008-04-25 2014-06-18 協和発酵キリン株式会社 Stable multivalent antibody
CN102361883A (en) 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 Bispecific anti-erbb-1/anti-c-met antibodies
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
JO3375B1 (en) * 2010-11-08 2019-03-13 Regeneron Pharma Human antibodies to human tnf-like ligand 1a (tl1a)
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2758438A1 (en) 2011-09-23 2014-07-30 Amgen Research (Munich) GmbH Bispecific binding molecules for 5t4 and cd3
CA2850549C (en) 2011-09-30 2023-03-14 Teva Pharmaceuticals Australia Pty Ltd. Antibodies against tl1a and uses thereof
SI2852615T1 (en) 2012-05-22 2019-02-28 Bristol-Myers Squibb Company Il-17a/f il-23 bispecific antibodies and their uses
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
CA2893562C (en) 2012-11-28 2023-09-12 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
AP2015008605A0 (en) 2013-01-02 2015-07-31 Glenmark Pharmaceuticals Sa Antibodies that bind to tl1a and their uses
TW201444867A (en) 2013-03-08 2014-12-01 Lilly Co Eli Anti-TNF-anti-IL-17 bispecific antibodies
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
WO2014144357A1 (en) 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
EA201890895A1 (en) * 2013-03-15 2019-02-28 Зинджения, Инк. MULTIVALENT AND MONOVALENT MULTIS-SPECIFIC COMPLEXES AND THEIR APPLICATION
UA118028C2 (en) * 2013-04-03 2018-11-12 Рош Глікарт Аг Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
PE20161092A1 (en) 2013-11-13 2016-10-28 Pfizer SPECIFIC ANTIBODIES FOR LIGAND 1A TYPE FACTOR OF TUMOR NECROSIS AND COMPOSITIONS AND USE OF THEM
US20160052006A1 (en) 2013-11-22 2016-02-25 Sheila S. Pirtle Spray Bottle

Also Published As

Publication number Publication date
JO3816B1 (en) 2021-01-31
IL259847A (en) 2018-07-31
ZA201904491B (en) 2020-03-25
CA3008267A1 (en) 2017-06-22
WO2017106383A1 (en) 2017-06-22
CL2021001179A1 (en) 2021-11-19
EA201891322A1 (en) 2019-01-31
SG10201912002YA (en) 2020-02-27
MA44060A (en) 2018-10-24
TW201731871A (en) 2017-09-16
WO2017106383A4 (en) 2017-09-08
EP3390444A1 (en) 2018-10-24
BR112018012096A2 (en) 2018-11-27
CN109311971A (en) 2019-02-05
US20190119407A1 (en) 2019-04-25
TWI799368B (en) 2023-04-21
JP2019502692A (en) 2019-01-31
AU2024200534A1 (en) 2024-04-11
AU2016370659A1 (en) 2018-06-28
UA124305C2 (en) 2021-08-25
CR20180365A (en) 2018-09-28
CL2023002597A1 (en) 2024-03-15
CL2018001596A1 (en) 2018-09-28
MX2018007424A (en) 2018-09-21
JP7263007B2 (en) 2023-04-24
UY37027A (en) 2017-06-30
US11104745B2 (en) 2021-08-31
KR20180099723A (en) 2018-09-05
TN2019000275A1 (en) 2021-05-07
CO2018007355A2 (en) 2018-07-19
US20220213226A1 (en) 2022-07-07
AU2016370659B2 (en) 2024-02-15
PH12018501284A1 (en) 2019-01-28

Similar Documents

Publication Publication Date Title
SG11201804857WA (en) Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
SG11201903867YA (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201906264YA (en) Improved serum albumin binders
SG11201906341XA (en) Improved serum albumin binders
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201900616UA (en) Engineered polypeptides and uses thereof
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201909395TA (en) Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
SG11201900573UA (en) Methods of purifying fc-containing proteins
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201907422RA (en) Anti-tau antibodies and methods of use thereof
SG11201808979UA (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
SG11201809089QA (en) Bispecific binding proteins and uses thereof
SG11201806992VA (en) Antibodies to tigit
SG11201903693QA (en) Polypeptide variants and uses thereof
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201907754RA (en) Anti-phf-tau antibodies and uses thereof
SG11201407644UA (en) Methods for making fully human bispecific antibodies using a common light chain
SG11201805420SA (en) Antibodies and conjugates thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201900744SA (en) Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them